Thomas Andrew Crockett, CEO at KalVista Pharmaceuticals, Inc. (KALV), sold 30,000 shares at $12.02 ($361K) on 2023-12-27, disclosed to the SEC on 2023-12-28.
Scheduled sale ($361k) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| KALV | SELL | 2024-02-05 | $162K | — | Filing → |
| KALV | SELL | 2023-11-21 | $244K | — | Filing → |
| KALV | SELL | 2023-08-21 | $319K | — | Filing → |